Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cancer
- Who it enrolls
- age 18 Years to no upper limit; female; excludes diabetes; BMI ≥27 required; conditions: Obesity (Disorder); Breast Cancer
- Interventions
- Tirzepatide
- Conditions
- Obesity (Disorder); Breast Cancer
- Phase and size
- Phase 4 · 30 participants
- Dates
- Start 2026-06-08
Primary completion 2027-12-03 - Sponsor
- Weill Medical College of Cornell University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Percentage of participants completing week 24 visit with all required assessments24 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Biologically female * Age ≥ 18 * Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry * Postmenopausal as defined by one or more of the following * Age ≥60 years * Age \<60 years with amenorrhea for ≥ 1 year * Documented bilateral surgical oophorectomy * Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial * HR+ (ER and/or PR) stage 0-III breast cancer * Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment * Insurance approval for tirzepatide or willing to pay out of pocket * Willing to provide informed consent and comply with study procedures Exclusion Criteria: * Stage IV breast cancer * Concomitant use of CDK inhibitors * Concomitant use of antiHER2 therapy * The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications * Other active malignancy requiring treatment * Enrollment in another investigational clinical trial * Contraindication to tirzepatide * Treatment with a GLP-1 receptor agonist within the last 3 months * Diabetes requiring insulin * Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol
03Change log
Registry changes
No changes recorded since the trial was added.